Related Experiment Video

Updated: Jul 19, 2026

Cell-Free DNA Extraction of Vitreous and Aqueous Humor Specimens for Diagnosis and Monitoring of Vitreoretinal Lymphoma
06:20

Cell-Free DNA Extraction of Vitreous and Aqueous Humor Specimens for Diagnosis and Monitoring of Vitreoretinal Lymphoma

Published on: January 12, 2024

Hepatitis C virus infection and MALT-type ocular adnexal lymphoma

P Arnaud, M-C Escande, M Lecuit

    Annals of Oncology : Official Journal of the European Society for Medical Oncology
    |October 27, 2006
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
    09:03

    The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

    Published on: February 3, 2012

    Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus
    11:18

    Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus

    Published on: May 7, 2012

    Related Experiment Videos

    Last Updated: Jul 19, 2026

    Cell-Free DNA Extraction of Vitreous and Aqueous Humor Specimens for Diagnosis and Monitoring of Vitreoretinal Lymphoma
    06:20

    Cell-Free DNA Extraction of Vitreous and Aqueous Humor Specimens for Diagnosis and Monitoring of Vitreoretinal Lymphoma

    Published on: January 12, 2024

    The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
    09:03

    The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

    Published on: February 3, 2012

    Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus
    11:18

    Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus

    Published on: May 7, 2012

    Related Concept Videos

    Cytomegalovirus Disease01:27

    Cytomegalovirus Disease

    Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
    Hepatitis01:25

    Hepatitis

    Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...

    Articles linked to this work by shared authors, journal, and citation graph.

    Imaging patterns and diagnostic challenges in metastatic invasive lobular carcinoma.

    European journal of radiology·2026

    Ultrasensitive circulating tumor DNA detection improves prognostication in triple-negative breast cancer postneoadjuvant therapy.

    ESMO open·2026

    Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survival.

    Annals of oncology : official journal of the European Society for Medical Oncology·2026

    Pathological complete response with neoadjuvant pembrolizumab and chemotherapy in non-metastatic triple-negative inflammatory breast cancer.

    ESMO open·2026

    18F-Fluorodeoxyglucose PET-CT evaluation after one course of neoadjuvant therapy fails to predict pCR in HER2 + BC patients: a prospective and multicentric French study.

    Breast cancer research : BCR·2025

    Real-world treatment patterns and effectiveness after disease progression on CDK4/6 inhibitors for HR-positive/HER2-negative metastatic breast cancer in the ESME-MBC cohort.

    ESMO open·2025

    Adjuvant pembrolizumab for the treatment of clear cell renal cell carcinoma: Five-year results from the phase III KEYNOTE-564 study.

    Annals of oncology : official journal of the European Society for Medical Oncology·2026

    Thymic Radiation is Associated with Worse Outcomes in Patients with NSCLC.

    Annals of oncology : official journal of the European Society for Medical Oncology·2026

    Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial.

    Annals of oncology : official journal of the European Society for Medical Oncology·2026

    Five-Year Outcomes of Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer From the Randomized KEYNOTE-671 Study.

    Annals of oncology : official journal of the European Society for Medical Oncology·2026

    Atezolizumab with or without tiragolumab in unresectable esophageal squamous cell carcinoma following definitive concurrent chemoradiotherapy (SKYSCRAPER-07): a randomised, phase III study.

    Annals of oncology : official journal of the European Society for Medical Oncology·2026

    Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER).

    Annals of oncology : official journal of the European Society for Medical Oncology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us